Positions Diverge In Cost-Conscious User-Fee Negotiations
This article was originally published in The Gray Sheet
As efforts to limit costs of device user-fee reauthorization intensify, the differences in FDA and industry priorities are increasingly on display in ongoing negotiations. In response to industry's call to pare down proposals, FDA returned to the table with a slimmer MDUFA proposal that did not satisfy the other side.
Register for our free email digests: